Sign In
Buy SNY
$43.48
+0.0200 (+0.0460%)
At Close: Aug 10, 2026
Sanofi: How I Leveraged This Undervalued Dividend Aristocrat
06:13am, Thursday, 06'th Aug 2026
Sanofi is rated a Buy, with ~33.5% upside to €99.5 fair value (or $57 for SNY ADRs), resulting from averaging optimistic with pessimistic scenarios. Dupixent remains Sanofi's key growth driver, with
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (August 2026)
08:24am, Wednesday, 05'th Aug 2026
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter
Press Release: Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
01:00am, Tuesday, 04'th Aug 2026
Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease Paris, August 4, 2026. Sanofi today announced that the European Commission (EC) has a
Sanofi (NASDAQ:SNY) Receives Consensus Recommendation of “Hold” from Analysts
04:15am, Monday, 03'rd Aug 2026
Sanofi (NASDAQ: SNY - Get Free Report) has been assigned a consensus recommendation of "Hold" from the fifteen brokerages that are presently covering the firm, MarketBeat.com reports. Ten equities res
Sanofi Beats on Q2 Earnings & Sales, Stock Down on Pipeline Setbacks
01:06pm, Thursday, 30'th Jul 2026
SNY beats on Q2 earnings and sales as Dupixent tops euro 5B in quarterly sales for the first time. The company also raises its 2026 outlook.
Sanofi Q2 Earnings Call Highlights
09:05am, Thursday, 30'th Jul 2026
Sanofi NASDAQ: SNY raised its 2026 outlook after reporting double-digit second-quarter sales and earnings growth, driven by Dupixent, recently launched medicines and cost discipline. The company also
Sanofi Raises Guidance as New CEO Looks to Revamp Drug Pipeline
01:44am, Thursday, 30'th Jul 2026
The company now expects 2026 sales to grow by around 10% excluding currency changes, with business earnings per share rising slightly faster than sales.
Sanofi raises sales outlook on Dupixent strength in boost for new CEO
01:34am, Thursday, 30'th Jul 2026
Sanofi on Thursday raised its full-year sales forecast on the back of strong demand for blockbuster asthma drug Dupixent, with investors focused on new CEO Belen Garijo's first address for her p
Bank of New York Mellon Corp Grows Holdings in Sanofi $SNY
03:59am, Wednesday, 29'th Jul 2026
Bank of New York Mellon Corp grew its position in Sanofi (NASDAQ: SNY) by 7.8% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 467,759 shares of the comp
The Smartest Dividend Stock to Buy With $1,000 Right Now (Spoiler: It Yields 5.6%.)
10:30pm, Tuesday, 28'th Jul 2026
Add the effect of stock buybacks to the dividend, and you're looking at a total yield approaching 11%.
Cetera Investment Advisers Buys 43,135 Shares of Sanofi $SNY
03:50am, Tuesday, 28'th Jul 2026
Cetera Investment Advisers increased its stake in Sanofi (NASDAQ: SNY) by 13.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commis
Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO
02:32am, Friday, 24'th Jul 2026
The drugmaker said efficacy and safety data didn't support further development of the drug, amlitelimab, for atopic dermatitis.
Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews
01:30am, Friday, 24'th Jul 2026
Sanofi today announced discontinuation of clinical development of amlitelimab, an OX40-ligand monoclonal antibody, in moderate-to-severe atopic dermatitis.
Press Release: Sanofi evolves its Executive Committee to support its next strategic chapter
12:00pm, Tuesday, 21'st Jul 2026
Sanofi evolves its Executive Committee to support its next strategic chapter Paris, July 21, 2026. Sanofi today announced an evolution of its Executive Committee, bringing together a focused leadershi
AI Bubble Risks Make Dividend Stocks Attractive Again
01:03pm, Saturday, 18'th Jul 2026
I identify dividend stocks and REITs that could protect investors from AI bubble risks, geopolitics, and inflation while generating attractive income. My "ALLKA Dividend Rating" model separates qualit
